Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Delayed Nyse 21:00:13 18/06/2024 BST 5-day change 1st Jan Change
891.5 USD +0.73% Intraday chart for Eli Lilly and Company +2.96% +52.93%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
A weight loss ETF MT
Health Care Flat as Traders Wait More Obesity-Drug Updates - Health Care Roundup DJ
Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup DJ
Investors need more time to assess Fed comments Our Logo
Musk wins pay approval but still faces Tesla's floundering stock and rich valuation RE
Employer coverage for weight-loss drugs rises sharply, survey finds RE
Eli Lilly Gets FDA Approval for Selpercatinib to Treat Thyroid Cancer MT
Novo Nordisk, Eli Lilly's Weight-Loss Drugs Coverage Dropped by Blue Cross Blue Shield of Michigan MT
Biogen executive plays down looming competition for its Alzheimer's drug RE
BIOGEN EXEC SAYS THE ALZHEIMER'S DRUG MARKET "WILL DEVELOP FASTE… RE
Social Buzz: Wallstreetbets Stocks Mixed Premarket Wednesday; Oracle to Advance, AST SpaceMobile to Open Lower MT
Alzheon, Inc Announces Appointment of Gino Santini to Board of Directors CI
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care Stocks Decline Tuesday Afternoon MT
Swiss Market Index Falls as US Rate Jitters Persist MT
Global markets live: GSK, Tesla, Intel, General Motors, Gamestop... Our Logo
Trending : Eli Lilly's Alzheimer's Treatment Gets FDA Advisory Panel Backing DJ
Dpa-AFX Overview: COMPANIES as of 11/06/2024 - 15:15 DP
Investors aren't fooled Our Logo
Futures ease on rate-cut jitters ahead of inflation data, Fed meet RE
FDA Panel Recommends Approval of Eli Lilly's Alzheimer's Drug Donanemab MT
Stocks Fall Pre-Bell Ahead of Fed Policy Meeting; Asia Churns, Europe Down MT
Futures fall as markets await Fed decision, CPI data RE
Jefferies Adjusts Price Target on Eli Lilly and Co. to $994 From $957 MT
Japan's Nikkei gains on chip shares boost; Fed policy in focus RE
Chart Eli Lilly and Company
More charts
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
891.5 USD
Average target price
855.4 USD
Spread / Average Target
-4.05%
Consensus
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. News Eli Lilly and Company
  5. China Grants Green Light to Eli Lilly's Diabetes Treatment
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW